ATTR-CM Treatment Pitch

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) is a progressive, rare, life-threatening disease in which nonfunctional proteins are deposited in the heart muscle, leading to a stiff/weak heart and difficulty pumping blood around the body. If left untreated, life expectancy from diagnosis is 2-5 years. Commonly prescribed drugs like ACE inhibitors and beta-blockers provide symptomatic relief, but can be potentially harmful.

ATTR-CM treatment represents a substantial global market with significant and rapid growth potential. In 2023, the global ATTR-CM market is estimated $>2B. By 2029, estimates range from $9B -$10B. Product X maximizes TTR stabilization, preventing amyloid formation, which can halt or prevent the development of ATTR-CM. The introduction of this second-generation transthyretin stabilizer is poised for greatness.

ART DIRECTOR/CD: LINDSAY OLSON

COPYWRITER/CD:  LISA LLEWELLYN

EXECUTIVE CREATIVE DIRECTOR: MICHELLE GREEN